BR112014001501A2 - moduladores alfa-2 adrenérgicos para tratamento de distúrbios visuais mediados por projeções visuais centrais do olho - Google Patents

moduladores alfa-2 adrenérgicos para tratamento de distúrbios visuais mediados por projeções visuais centrais do olho

Info

Publication number
BR112014001501A2
BR112014001501A2 BR112014001501A BR112014001501A BR112014001501A2 BR 112014001501 A2 BR112014001501 A2 BR 112014001501A2 BR 112014001501 A BR112014001501 A BR 112014001501A BR 112014001501 A BR112014001501 A BR 112014001501A BR 112014001501 A2 BR112014001501 A2 BR 112014001501A2
Authority
BR
Brazil
Prior art keywords
visual
mediated
eye
modulators
treating
Prior art date
Application number
BR112014001501A
Other languages
English (en)
Inventor
C Foster Alan
W Gil Daniel
E Donello John
V Staubli Ursula
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112014001501A2 publication Critical patent/BR112014001501A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

abstract the present invention relates to a method for treating visual disorders mediated by lateral geniculate nucleus, superior colliculus and the visual cortex by administering to a patient in need of such treatment, compounds acting at the alpha 2 adrenergic receptors. tradução: resumo patente de invenção: "moduladores alfa-2 adrenérgicos para tratamento de distúrbios visuais mediados por projeções visuais centrais do olho". a presente invenção refere-se a um método para tratamento de distúrbios visuais mediados pelos núcleo geniculado lateral, colículo superior e córtex cerebral através de administração a um paciente com necessidade de tal tratamento de compostos que agem nos receptores alfa 2 adrenérgi-cos.
BR112014001501A 2011-07-22 2012-07-17 moduladores alfa-2 adrenérgicos para tratamento de distúrbios visuais mediados por projeções visuais centrais do olho BR112014001501A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161510521P 2011-07-22 2011-07-22
PCT/US2012/047064 WO2013016073A1 (en) 2011-07-22 2012-07-17 Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye

Publications (1)

Publication Number Publication Date
BR112014001501A2 true BR112014001501A2 (pt) 2017-02-14

Family

ID=46551952

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014001501A BR112014001501A2 (pt) 2011-07-22 2012-07-17 moduladores alfa-2 adrenérgicos para tratamento de distúrbios visuais mediados por projeções visuais centrais do olho

Country Status (11)

Country Link
US (1) US20130023573A1 (pt)
EP (1) EP2734200A1 (pt)
JP (1) JP2014521643A (pt)
CN (1) CN103826628A (pt)
AU (1) AU2012287243A1 (pt)
BR (1) BR112014001501A2 (pt)
CA (1) CA2842866A1 (pt)
IL (1) IL230581A0 (pt)
MX (1) MX2014000871A (pt)
RU (1) RU2014105894A (pt)
WO (1) WO2013016073A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116186A1 (en) * 2012-01-30 2013-08-08 Allergan, Inc. Brimonidine for treating visual disorders mediated by central visual projections from the eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
DK3566703T3 (da) 2009-02-13 2021-07-05 Allergan Inc Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
BR112012018154A2 (pt) * 2010-01-21 2016-04-05 Allergan Inc agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular
US8501796B2 (en) * 2010-09-16 2013-08-06 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure

Also Published As

Publication number Publication date
CN103826628A (zh) 2014-05-28
AU2012287243A1 (en) 2014-02-20
CA2842866A1 (en) 2013-01-31
JP2014521643A (ja) 2014-08-28
EP2734200A1 (en) 2014-05-28
RU2014105894A (ru) 2015-08-27
WO2013016073A1 (en) 2013-01-31
MX2014000871A (es) 2014-06-23
IL230581A0 (en) 2014-03-31
US20130023573A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
NZ704247A (en) Compositions and treatment for eye diseases and disorders
MX356865B (es) Nuevas soluciones terapéuticas para tratar la enfermedad de parkinson.
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112012017073A2 (pt) Método de tratamento de condições neurológicas com glicosídeos cardíacos
BR112014010803A2 (pt) método de tratamento
MX2013012526A (es) Métodos para tratar la enfermedad de alzheimer, enfermedad de huntington, autismo u otros trastornos.
BR112014005389A8 (pt) Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
GB201317446D0 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
BR112014014378A2 (pt) composição e uso da mesma para tratar doença ocular relacionada a ácido nucleico
BR112013031652A2 (pt) métodos de tratamento para doenças retinais
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
MX2021006985A (es) Metodos para el tratamiento de la depresión.
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112014030813A2 (pt) tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson
AR092103A1 (es) Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1)
EA201691567A1 (ru) Способы лечения легких травм головного мозга
MX2013008715A (es) Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco.
BR112014011223A2 (pt) método de tratar uma doença proliferativa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]